New Treatment for Duchenne Muscular Dystrophy

* Deflazacort (Emflaza) is the first corticosteroid approved by the Food and Drug Administration for the treatment of Duchenne muscular dystrophy. * Adverse effects of deflazacort include weight gain, Cushingoid appearance, and an increased risk of infections.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research